Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT05361720
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 240
- Registration Number
- NCT05327686
- Locations
- 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Dayton Physicians LLC-Atrium, Franklin, Ohio, United States
🇺🇸Miami Valley Cancer Care and Infusion, Greenville, Ohio, United States
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Alfredo Berruti
- Target Recruit Count
- 32
- Registration Number
- NCT05265988
- Locations
- 🇮🇹
Alfredo Berruti, Brescia, Italy
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT05263050
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 6
- Registration Number
- NCT05249114
- Locations
- 🇺🇸
Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
- Conditions
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 24
- Registration Number
- NCT05241561
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Besançon, Besançon, France
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 4
- Registration Number
- NCT05200143
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 20
- Registration Number
- NCT05188118
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Conditions
- Locally Advanced Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Metastatic Hepatocellular CarcinomaUnresectable Hepatocellular CarcinomaStage IVA Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 122
- Registration Number
- NCT05168163
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Rapid City Regional Hospital, Rapid City, South Dakota, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
A Study of Cabozantinib As a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT05135975
- Locations
- 🇺🇸
Children's Hospital at Montefiore, Bronx, New York, United States
🇺🇸Children's Hospital of Alabama/UAB, Birmingham, Alabama, United States
🇺🇸Children's Hospital of Colorado, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.